While data on the heart and stroke risks of testosterone enhancers have been mixed, the FDA has held firm on its position that Low T drugs should be used only for medical conditions and not as a lifestyle drugs. Now the FDA says drugmakers need to provide new data on the heart and stroke risks of using them to boost testosterone in aging men. But, to save everybody a lot of time, effort and cost, it would be great if the drugmakers would do the clinical trial work together.
The argument for that is laid out in a piece appearing in Thursday's issue of the New England Journal of Medicine, according to Medscape. In the piece, penned by Dr. Christine Nguyen, a deputy director of Safety in the FDA's office of drug evaluation, and other experts, experts point out that while there has been a big increase in the use of the drugs to treat older men whose sex drive has waned, the benefits and risks of doing that have not been determined. In the piece, the authors encourage "companies to work together on a single trial."
AbbVie ($ABBV), which makes Androgel, and Eli Lilly ($LLY), maker of Axiron, in statements suggested they might be open to the idea. An AbbVie spokesperson said in an email: "AbbVie and other sponsors of prescription testosterone treatments are working with the FDA to determine the best path forward for a clinical trial." J. Scott MacGregor, Eli Lilly's global communications director, said: "We're continuing to work closely with the FDA in the best interests of men who use testosterone therapy."
The FDA has looked at a couple of metadata and other studies, but the populations in each were different and the findings mixed. The agency in March told drugmakers it wanted them to add to labels info about potential heart attack and stroke risks, and advised docs not to prescribe the drugs for age-related symptoms. That came after an advisory panel last year voted 14-1 to restrict testosterone-replacement therapies to men with a related medical condition such as a tumor or genetic disorder.
Even ahead of the FDA call for laying out the risks, AbbVie, Lilly and others reported waning sales for their products and said investors could expect further declines from the Low T drugs.